AM-Pharma is a biopharma company developing a proprietary recombinant human Alkaline Phosphatase (recAP) against Acute Kidney Injury, Inflammatory Bowel Disease and Hypophosphatasia.
AM-Pharma – recombinant human Alkaline Phosphatase
Alkaline Phosphatase (AP) is assumed to act as a detoxifying agent by removing phosphate from extracellular substrates. The dephosphorylation of pro-inflammatory substances like lipopolysaccharides (LPS) and extracellular ATP is assumed to play an important role. AM-Pharma discovered that a key function of Alkaline Phosphatase is to protect organs against inflammation and tissue damage. Indeed, Alkaline Phosphatase is found at reduced levels in certain conditions including Acute Kidney Injury (AKI), Ulcerative Colitis (UC) and Hypophosphatasia (HPP). Clinical proof-of-concept came from the positive results from Phase II clinical studies using native bovine AP, which demonstrated efficacy in patients with AKI and in patients with Moderate-to-Severe UC (a form of Inflammatory Bowel Disease). AM-Pharma develops its proprietary recombinant human Alkaline Phosphatase (recAP) therapeutics, in order to transform the treatment prospects for patients with chronic or life-threatening inflammatory diseases. AM-Pharma’s lead product, an intravenous formulation of recAP, is currently being investigated in a large Phase II clinical study in patients with sepsis-associated AKI. With no current treatments available, an estimated 2 million AKI patients in the western world and an estimated 10 billion dollar healthcare cost for AKI supportive care in the US, a therapy would be very welcome.
Founded in 2001, AM-Pharma is a biopharma company based in Bunnik (Netherlands). AM-Pharma’s management team is highly experienced in drug development. Management Team is composed by Erik van den Berg, Steve Connor, Peter Verwayen, Andrea van Elsas, Tim Knotnerus and Jacques Arend. The Company is also supported by an internationally-renowned Scientific Advisory Board as well as a Supervisory Board comprised of senior level executives associated with leading life science venture capital firms. Scientific Advisory Board is composed by Sander van Deventer, Ravindra Mehta, William Sandborn, Jean-Louis Vincent, Can Ince, Joannidis and Patrick Honoré. And supervisory Board is composed by Russell Greig, Geert-Jan Mulder, David Donabedian, Edwin de Graaf, Klaus Breiner, Guido Magni, Ashok Dhanrajgir, Rémi Droller and Joël Jean-Mairet. The Company is backed by strong international investors and has raised over €65 million equity to date.
More about AM-Pharma: www.am-pharma.com